Please login to the form below
overactive bladder
This page shows the latest overactive bladder news and features for those working in and with pharma, biotech and healthcare.
Urovant slips on phase 3 incontinence drug data
The phase 3 EMPOWUR trial of vibegron in patients with incontinence caused by overactive bladder (OAB) showed that the beta-3 adrenergic agonist performed significantly better than placebo on the two
Latest news
-
Daily Brief: setback for Akcea/Ionis, Urovant adds gene therapy, Metrion gains funding
Urovant Sciences has licensed a novel gene therapy for patients with overactive bladder (OAB) symptoms who have failed oral pharmacologic therapy. ... There are no currently available FDA-approved gene therapy treatments for overactive bladder.
-
Daily Brief: Limited NICE recommendation for Fasenra, Urovant takes aim at an IPO, Xtandi expands use
The proceeds will fund phase III trials of its overactive bladder treatment candidate vibegron, which it in-licensed last year from Merck &Co. ... Urovant aims to investigate the drug’s use in overactive bladder (OAB), as well as another trial in OAB
-
Allergan pushes on with Botox for depression
overactive in depression. ... Aside from its use as a wrinkle treatment Botox is already approved to treat various medical conditions, including chronic migraine, excessive sweating and overactive bladder among others, and is Allergan's
-
Size matters?
Clinical trials are ongoing to test its application against overactive bladder and migraine.
-
Astellas sells dermatology unit to Leo for €675m
The overarching aim is to prepare for the forthcoming patent expiries on big-selling drugs Vesicare (solifenacin succinate) for overactive bladder and cancer therapy Tarceva (erlotinib).
More from news
Approximately 4 fully matching, plus 44 partially matching documents found.
Latest Intelligence
-
Astellas: Ten years young
In Europe we have been launching a product almost every single year,” notes Ken, pointing to products such as the overactive bladder (OAB) drug Betmiga (mirabegron) - the first of a new
-
Allergan and taking a specialised approach
In addition to migraine and adult spasticity, its approved indications include overactive bladder, muscle stiffness in elbow, wrist and fingers, muscle problems in the eye, crow's feet lines and severe
-
Interview: Kay Drake and Naoki Okamura, Astellas
For example, we are a GCL in urology; we have Vesicare, which has 40 per cent market share in the overactive bladder (OAB) market. ... From an OAB perspective, we support the Bladder and Bowel Foundation here in the UK, which provides a patient advice
-
Show stopper exposes taboo
As part of a national campaign called A Matter of Urgency’, the show-stopping garden was designed to raise awareness of Overactive Bladder which affects nearly one in five people in ... Nearly one in five people in the UK over 40 have an overactive
-
Interview: Ken Jones, Astellas Pharma Europe
Urology is a key strategic area for Astellas and we have a strong pipeline in this therapy area; we are currently getting prepared with Mirabegron, a drug to treat overactive bladder,
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest from PMHub
-
emotive boosts health economics and outcomes research team
His MSc project involved performing a health economic evaluation of the cost-effectiveness of different overactive bladder treatments available in the UK. ... The appointment of Trishal, with his specific expertise in visual science and overactive bladder
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Senior / Principal Medical Writer - MedComms - Home Based / Vari...
-
Excellent Remuneration Packages
- Senior Account Director/ Associate Director- Pharma and Life Sci...
-
Competitive salary and benefits
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
-
Director – Healthcare PR
-
Salary TBC
- Account Manager / Senior Account Manager - Healthcare Advertisin...
-
Excellent Remuneration
- Senior Account Manager- Pharma and Life Scienes
-
Competitive salary and benefits
- Account Director – London based Medical Communications Agency
-
Excellent Remuneration Package
-
Senior Medical Writer
-
Salary TBC
-
Account Director, Medical Education
-
Salary TBC
- Project Manager - Medical Communications – South Wales
-
Excellent Remuneration Package
- Project Manager - Digital Healthcare - London
-
Excellent Remuneration Package
- Freelance Medical Writer - Healthcare Advertising - London
-
Employment Type:. Type of Job:. Region:. Salary:. 250 to 330 per day
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Editor – Medical Education Agency – Bucks
-
Salary TBC
- Experienced / Senior Account Director - Publications - London
-
Up to £80, 000 plus great benefits
-
Senior Medical Writer
-
Competitive salary and benefits
Subscribe to our email news alerts
- Lucid Group announces the appointment of new CFO
- From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
- Q&A: Niels Lund
- The Pharma Brand Planners’ Blog: Part 1
- Novartis makes case for gene therapy Zolgensma in SMA
- Adding different perspectives to scientific communications at Porterhouse Medical
PMHub
Syneos Health™
Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...
Latest intelligence
- From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
- How pharma is progressing their commitment in patient engagement...
- Cuttsy+Cuttsy awarded CPD Platinum by the IPA
- Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
- Breaking Bad
- Six behaviours separate the good brand teams from the bad...
Quick links
Infographics
